Compare ODC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ODC | ERAS |
|---|---|---|
| Founded | 1941 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 895.7M | 5.5B |
| IPO Year | 1994 | 2021 |
| Metric | ODC | ERAS |
|---|---|---|
| Price | $71.55 | $17.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $12.08 |
| AVG Volume (30 Days) | 47.1K | ★ 5.0M |
| Earning Date | 03-11-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.14% | N/A |
| EPS Growth | ★ 50.45 | 36.23 |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $485,572,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $42.70 | ★ N/A |
| Revenue Growth | ★ 10.97 | N/A |
| 52 Week Low | $41.37 | $1.06 |
| 52 Week High | $73.46 | $18.20 |
| Indicator | ODC | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 71.52 | 63.75 |
| Support Level | $58.40 | $1.72 |
| Resistance Level | N/A | $18.20 |
| Average True Range (ATR) | 1.85 | 1.30 |
| MACD | 0.82 | 0.01 |
| Stochastic Oscillator | 86.87 | 88.45 |
Oil-Dri Corp of America develops, manufactures, and markets sorbent products made predominantly from clay. Its absorbent offerings, which draw liquid up, include cat litter, floor products, toxin control substances for livestock, and agricultural chemical carriers. The company has two segments based on the different characteristics of two primary customer groups, namely the Retail and Wholesale Products Group, which derives maximum revenue, and the Business-to-Business Products Group. The company's products are sold under various brands such as Cat's Pride, Jonny Cat, Amlan, Agsorb, Verge, Pure-Flo, and Ultra-Clear.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.